Salarius Pharmaceuticals and Decoy Therapeutics announce merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2025
0mins
Should l Buy ?
Merger Announcement: Salarius Pharmaceuticals has signed an agreement to merge with Decoy Therapeutics, which will result in a new company named Decoy Therapeutics led by Decoy’s co-founders and Salarius’ CFO.
Ownership Structure: After the merger, Decoy investors are expected to own approximately 86% of the merged company, while Salarius stockholders will hold about 14%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
